Self assembly Biological molecules are important lines to understand the molecular basis of complex metabolic events. The presence of cosolvent in aqueous solution during the self-assembly process can promote the formation of a metasable intermediary that is trapped in Kina. In nature, cosolvents categories called osmolytes can work to strengthen hydrogen bond tissue in such a way that the original conditions of certain proteins are preferred, thus modulating their functions and stability. However, identifying COSOLVENTs that act as osmolytes in biomimetic applications, such as self-assignment of soft materials, remain challenging.
This work examines the effects of ethanol (ETOH) and acetonitrile (ACN) as cosolven at the self-assignment of Amphiphilic Polypeptide PSAR30- (L-LEU-AIB) 6 (S30L12), which combines α-helical hydrophobic blocks, in aqueous solution. The result gives direct observation of the morphological behavior of S30L12 as a function of solvent composition. Morfological transitions are investigated using electron microscope transmissions, while peptide molecular packaging is assessed using circular blocked analysis and evaluating membrane fluidity.
In the mixture of Etoh / H2O, EtOH strengthens the water hydrogen bond tissue, thus limiting the hydrophobic hydration of the S30L12 assembly and increasing hydrophobic interactions between assemblies. Conversely, ACN forms its own nanoclusters in water and on the hydrophobic core of peptide assemblies to stabilize the edges exposed to bulk water and increase assembly kinetics. Fourier Transform Infrared Analysis (FT-IR) shows that EtOH and ACN can modify biomaterial self assembly in the same way as protective or denaturant osmolyte.
Poisonous polypeptide production as fusion inside the recit cavity
This system was developed for efficient biosynthetic production of painsty polypeptides. A polipeptide target produced blends into the T. thermophilus tassel polpeptide in such a way that it is served in the purai cavity near the substrate binding surface. Such presentations allow the relieve potential issues instability, toxicity or peptide hydrophobicity that blends. Thermostilical thermostabilities can be used to separate a one-step from the host cell protein by heating. The target of polypeptides can be released by special chemical care amino acids.
In this study, Groel was adapted for special methionine cleavage with cyanogen bromide with a total metionine residue replacement to facilitate further purification of the polipeptide target. The procedure is simple, strong, and easy to improve. The capacity of this system to produce polypeptides that is difficult to express is shown by production in the bacterial system from one of the most powerful antibacterial peptides polyphemusin I.
Adenilaty Adenilaty Polypeptide Adenilaty Cyclase: Neuroprotective Peptides that Promise in Stroke
Searching for effective and effective care for acute strokes continues to be a global priority due to high mortality and morbidity. Terapeutic treatment currently has limited effects, making searches for imperative new care. Polypeptides in the pituitary clasp (Pacip) are established cytoprotective neuropeptide participating in various physiological and pathological activities of nerves, such as neuron proliferation, differentiation, and migration, and neuroprotection. This is considered a promising treatment in many neurological diseases.
Thus, PACAP bears potential as a new therapeutic strategy for stroke treatment. Here, we provide an overview that is related to the current PACAP knowledge, its receptors, and the potential role of neuroprotective in stroke settings, as well as various neuroprotecting mechanisms involving ion homeostasis, excitoxicity, cell edema, and oxidative stress ,, and cell death, and the route of giving Pacap.
Polypeptide Amyloid Islet & Beta Amyloid Peptide Role In Alzheimer’s Disease: Two Triggers, One Disease
Alzheimer’s disease (AD) is a neurodegenerative disorder that affects millions throughout the world. Because of the aging of the population, advertising events increase. Ad patients develop cognitive and dementia decreases, known features, requires permanent care. This raises the main socio-economic burden on the health care system because relatives and health workers are patients forced to overcome the increasing number of people affected. Despite the latest advances, the pathological mechanism of advertising is not fully understood.
However, it is clear that the amyloid beta (Aβ) peptide, which forms amyloid plaque in the brain of AD patients, plays a key role. Type 2 diabetes, the most common form of diabetes, affects hundreds of millions of people globally. The amyloid polypeptide (IAPP) islet is a hormone produced and released by insulin in the β-β pancreas, with a key role of diabetes, because it helps regulate glucose levels and control adiposity and pursuit. Likewise with Aβ, IAPP is very amyloidogenic, produces intracellular amyloid deposits that cause β cell dysfunction and death.
Peptide T |
|||
| 057-01 | PHOENIX PEPTIDE | 5 mg | EUR 140.4 |
FGL Peptide |
|||
| 073-36 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
APK peptide |
|||
| 076-81 | PHOENIX PEPTIDE | 200 μg | EUR 199.8 |
NEF peptide |
|||
| 076-83 | PHOENIX PEPTIDE | 500 μg | EUR 140.4 |
SHA peptide |
|||
| 076-84 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
YSY peptide |
|||
| 076-86 | PHOENIX PEPTIDE | 100 μg | EUR 230.04 |
PSTAIR Peptide |
|||
| 070-61 | PHOENIX PEPTIDE | 500 μg | EUR 129.6 |
PGMtide Peptide |
|||
| 040-69 | PHOENIX PEPTIDE | 100 μg | EUR 316.44 |
Peptide E / 3200-Dalton Adrenal Enkephalin-Containing Peptide (Bovine) |
|||
| 024-57 | PHOENIX PEPTIDE | 200 μg | EUR 86.4 |
Adjuvant Peptide |
|||
| 070-05 | PHOENIX PEPTIDE | 500 μg | EUR 36.72 |
proSex peptide (20-55) |
|||
| 040-30 | PHOENIX PEPTIDE | 100 μg | EUR 355.32 |
proSex peptide (28-55) |
|||
| 040-31 | PHOENIX PEPTIDE | 100 μg | EUR 282.96 |
proSex peptide (40-55) |
|||
| 040-32 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
Peptide-epsilon |
|||
| 058-22 | PHOENIX PEPTIDE | 500 μg | EUR 114.48 |
Delicious Peptide |
|||
| 070-21 | PHOENIX PEPTIDE | 5 mg | EUR 160.92 |
Peptide F-9 |
|||
| 038-06 | PHOENIX PEPTIDE | 200 μg | EUR 58.32 |
Sturgeon Peptide (137-158) |
|||
| 021-94 | PHOENIX PEPTIDE | 100 μg | EUR 177.12 |
NGR Peptide 1 |
|||
| 025-74 | PHOENIX PEPTIDE | 200 μg | EUR 184.68 |
Peptide Lv (Rat) |
|||
| 008-73 | PHOENIX PEPTIDE | 100 μg | EUR 469.8 |
Bombinin-Like Peptide 1 amide / prepro-Bombinin-Like Peptide (44-70) amide / prepro-Bombinin-Like Peptide (107-133) amide |
|||
| 007-60 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
Bid BH3 peptide |
|||
| 025-87 | PHOENIX PEPTIDE | 1 mg | EUR 170.64 |
AF-16 Peptide |
|||
| 033-44 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Anorexigenic Peptide |
|||
| 070-10 | PHOENIX PEPTIDE | 5 mg | EUR 86.4 |
GnRH Associated Peptide (GAP) (1-13) / GnRH Precursor Peptide (14-26) (Human) |
|||
| 029-03 | PHOENIX PEPTIDE | 500 μg | EUR 114.48 |
GnRH Associated Peptide (GAP) (1-24) / GnRH Precursor Peptide (14-37) (Human) |
|||
| 029-04 | PHOENIX PEPTIDE | 100 μg | EUR 114.48 |
GnRH Associated Peptide (GAP) (1-53) / GnRH Precursor Peptide (14-66) (Human) |
|||
| 029-05 | PHOENIX PEPTIDE | 20 μg | EUR 267.84 |
GnRH Associated Peptide (GAP) (25-53) / GnRH Precursor Peptide (38-66) (Human) |
|||
| 029-06 | PHOENIX PEPTIDE | 100 μg | EUR 114.48 |
Peptide Lv (Human) |
|||
| 008-71 | PHOENIX PEPTIDE | 100 μg | EUR 405 |
Peptide Lv (Mouse) |
|||
| 008-72 | PHOENIX PEPTIDE | 100 μg | EUR 469.8 |
Peptide B (Bovine) |
|||
| 024-56 | PHOENIX PEPTIDE | 200 μg | EUR 81 |
Peptide F (Bovine) |
|||
| 024-58 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
ExE peptide M3mP6 |
|||
| 064-33 | PHOENIX PEPTIDE | 200 μg | EUR 244.08 |
GnRH Associated Peptide (GAP) (1-13) / Gn-RH Precursor Peptide (14-26) (Rat) |
|||
| 029-08 | PHOENIX PEPTIDE | 200 μg | EUR 64.8 |
PLP Peptide (103-116) (Bovine) |
|||
| 070-14 | PHOENIX PEPTIDE | 5 mg | EUR 140.4 |
FMRF-Like Peptide |
|||
| 047-32 | PHOENIX PEPTIDE | 1 mg | EUR 27 |
Joining Peptide (Rat) |
|||
| 047-91 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
Peptide T (4-8) |
|||
| 057-04 | PHOENIX PEPTIDE | 500 μg | EUR 64.8 |
Peptide T (5-8) |
|||
| 057-05 | PHOENIX PEPTIDE | 500 μg | EUR 64.8 |
Growth Hormone-Releasing Peptide-Related Peptide-1 (fGRP-RP-1) (Frog) |
|||
| 048-80 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
Growth Hormone-Releasing Peptide-Related Peptide-2 (fGRP-RP-2) (Frog) |
|||
| 048-81 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Growth Hormone-Releasing Peptide-Related Peptide-3 (fGRP-RP-3) (Frog) |
|||
| 048-82 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Opioid Peptide Library |
|||
| L-002 | PHOENIX PEPTIDE | 58 peptides | EUR 2691.36 |
Vasonatrin Peptide (VNP) |
|||
| 005-47 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
[D-Ala1]-Peptide T |
|||
| 057-02 | PHOENIX PEPTIDE | 5 mg | EUR 282.96 |
Heparin Binding Peptide |
|||
| 025-47 | PHOENIX PEPTIDE | 500 μg | EUR 102.6 |
Gastrin Related Peptide |
|||
| 027-09 | PHOENIX PEPTIDE | 5 mg | EUR 73.44 |
PGMtide Control Peptide |
|||
| 040-70 | PHOENIX PEPTIDE | 100 μg | EUR 316.44 |
Growth Blocking Peptide |
|||
| 046-92 | PHOENIX PEPTIDE | 100 μg | EUR 255.96 |
Neuron Specific Peptide |
|||
| 047-55 | PHOENIX PEPTIDE | 200 μg | EUR 140.4 |
Obesity Peptide Library |
|||
| L-003 | PHOENIX PEPTIDE | 160 peptides | EUR 7267.32 |
Peptide YY (PYY) (Human) |
|||
| 059-01 | PHOENIX PEPTIDE | 200 μg | EUR 119.88 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) |
|||
| 064-01 | PHOENIX PEPTIDE | 200 μg | EUR 108 |
proSex peptide (28-55) - EIA Kit |
|||
| EK-040-31 | PHOENIX PEPTIDE | 96 wells | EUR 603.72 |
Peptide F 1 (Lobster) |
|||
| 047-62 | PHOENIX PEPTIDE | 500 μg | EUR 73.44 |
Eledoisin Related Peptide |
|||
| 046-04 | PHOENIX PEPTIDE | 5 mg | EUR 58.32 |
Morphine Tolerance Peptide |
|||
| 050-13 | PHOENIX PEPTIDE | 1 mg | EUR 102.6 |
Phosphate Acceptor Peptide |
|||
| 058-24 | PHOENIX PEPTIDE | 500 μg | EUR 73.44 |
FGL Peptide - Cy3 Labeled |
|||
| FC3-073-36 | PHOENIX PEPTIDE | 1 nmol | EUR 672.84 |
FGL Peptide - Cy5 Labeled |
|||
| FC5-073-36 | PHOENIX PEPTIDE | 1 nmol | EUR 756 |
FGL Peptide - FAM Labeled |
|||
| FG-073-36A | PHOENIX PEPTIDE | 1 nmol | EUR 405 |
Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia brasiliana) |
|||
| 047-39 | PHOENIX PEPTIDE | 200 μg | EUR 444.96 |
Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia brasiliana) |
|||
| 047-40 | PHOENIX PEPTIDE | 500 μg | EUR 214.92 |
Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia californica) |
|||
| 047-42 | PHOENIX PEPTIDE | 200 μg | EUR 444.96 |
Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia californica) |
|||
| 047-43 | PHOENIX PEPTIDE | 500 μg | EUR 214.92 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) |
|||
| 064-07 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
Pedal Peptide (Pep) (Aplysia) |
|||
| 047-61 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
Insulin B (22-25) Peptide |
|||
| 035-08 | PHOENIX PEPTIDE | 5 mg | EUR 86.4 |
ExE peptide M3mP6 mutant |
|||
| 064-35 | PHOENIX PEPTIDE | 200ug | EUR 234.36 |
ExE peptide M3mP6 mutant |
|||
| 064-37 | PHOENIX PEPTIDE | 200ug | EUR 234.36 |
FGL Peptide - FITC Labeled |
|||
| FG-073-36B | PHOENIX PEPTIDE | 1 nmol | EUR 405 |
AF-16 Peptide - Antibody |
|||
| H-033-44 | PHOENIX PEPTIDE | 100 μl | EUR 336.96 |
Schizophrenia Related Peptide |
|||
| 047-79 | PHOENIX PEPTIDE | 5 mg | EUR 44.28 |
Cell Penetrating ARF Peptide (26-44) |
|||
| 068-56 | PHOENIX PEPTIDE | 500 μg | EUR 640.44 |
Eosinophilotactic Peptide (AGSE) |
|||
| 070-28 | PHOENIX PEPTIDE | 5 mg | EUR 27 |
Eosinophilotactic Peptide (VGSE) |
|||
| 070-29 | PHOENIX PEPTIDE | 5 mg | EUR 27 |
FGL Peptide - Biotin Labeled |
|||
| B-073-36 | PHOENIX PEPTIDE | 20 μg | EUR 405 |
Peptide F (Bovine) - Antibody |
|||
| H-024-58 | PHOENIX PEPTIDE | 50 μl | EUR 238.68 |
Brain Peptide (Bees) Library |
|||
| L-007 | PHOENIX PEPTIDE | 51 peptides | EUR 6456.24 |
Peptide R / CXCR4 Antagonist |
|||
| 030-25 | PHOENIX PEPTIDE | 200 μg | EUR 203.04 |
PGMtide Peptide - Cy3 Labeled |
|||
| FC3-040-69 | PHOENIX PEPTIDE | 1 nmol | EUR 925.56 |
PGMtide Peptide - FAM Labeled |
|||
| FG-040-69A | PHOENIX PEPTIDE | 5 nmol | EUR 537.84 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - RIA Kit |
|||
| RK-064-01 | PHOENIX PEPTIDE | 125 tubes | EUR 932.04 |
[D-Arg14, D-Arg15]-MGF Peptide amide / C-terminal peptide of IGF-1 Ec amide |
|||
| 033-34 | PHOENIX PEPTIDE | 100 μg | EUR 177.12 |
Gastrointestinal Peptide Library |
|||
| L-006 | PHOENIX PEPTIDE | 200 peptides | EUR 7267.32 |
[D-Ala1]-Peptide T amide |
|||
| 057-03 | PHOENIX PEPTIDE | 500 μg | EUR 140.4 |
Peptide F (Bovine) - RIA Kit |
|||
| RK-024-58 | PHOENIX PEPTIDE | 125 tubes | EUR 932.04 |
Catch-Relaxing Peptide (CARP) |
|||
| 047-20 | PHOENIX PEPTIDE | 1 mg | EUR 199.8 |
Calmodulin Binding Peptide 1 |
|||
| 070-17 | PHOENIX PEPTIDE | 20 μg | EUR 214.92 |
FGL Peptide - Rhodamine Labeled |
|||
| FR-073-36 | PHOENIX PEPTIDE | 1 nmol | EUR 537.84 |
Peptide-Depleted Plasma (Rat) |
|||
| MB-099-02 | PHOENIX PEPTIDE | 2 ml | EUR 119.88 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - Antibody |
|||
| H-064-07 | PHOENIX PEPTIDE | 50 μl | EUR 238.68 |
Urokinase-Derived Peptide A6 |
|||
| 025-12 | PHOENIX PEPTIDE | 500 μg | EUR 129.6 |
PGMtide Peptide - Biotin Labeled |
|||
| B-040-69 | PHOENIX PEPTIDE | 20 μg | EUR 537.84 |
Anti-Inflammatory Peptide 1 |
|||
| 004-01 | PHOENIX PEPTIDE | 200 μg | EUR 27 |
Anti-Inflammatory Peptide 2 |
|||
| 004-02 | PHOENIX PEPTIDE | 200 μg | EUR 27 |
Anti-Inflammatory Peptide 3 |
|||
| 004-03 | PHOENIX PEPTIDE | 200 μg | EUR 27 |
Peptide 34 / GPR-54 Agonist |
|||
| 048-94 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
FGL Peptide - I-125 Labeled |
|||
| T-073-36 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - RIA Kit |
|||
| RK-064-07 | PHOENIX PEPTIDE | 125 tubes | EUR 932.04 |
Glycogenolysis-Inhibiting Peptide |
|||
| 023-63 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
Peptide-Depleted Plasma (Human) |
|||
| MB-099-01 | PHOENIX PEPTIDE | 2 ml | EUR 119.88 |
F3 Peptide / HMGN2 Fragment 3 |
|||
| 004-12 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
Peptide YY (PYY) (3-36) (Human) |
|||
| 059-02 | PHOENIX PEPTIDE | 200 μg | EUR 102.6 |
Fibronectin CS1 Peptide (EILDVPST) |
|||
| 025-20 | PHOENIX PEPTIDE | 500 μg | EUR 86.4 |
Myosin Kinase Inhibiting Peptide |
|||
| 058-20 | PHOENIX PEPTIDE | 500 μg | EUR 50.76 |
Antimicrobial Trp-rich peptide |
|||
| 004-05 | PHOENIX PEPTIDE | 100 μg | EUR 140.4 |
Peptide YY (PYY) (Human) - Antibody |
|||
| H-059-01 | PHOENIX PEPTIDE | 100 μl | EUR 469.8 |
Peptide A / p60v-src (137-157) |
|||
| 058-21 | PHOENIX PEPTIDE | 500 μg | EUR 135 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - FAM Labeled |
|||
| FG-064-07A | PHOENIX PEPTIDE | 1 nmol | EUR 336.96 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - I-125 Labeled |
|||
| T-064-01 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
PGMtide Peptide - Rhodamine Labeled |
|||
| FR-040-69 | PHOENIX PEPTIDE | 5 nmol | EUR 604.8 |
Anti-Angiogenic Peptide Library |
|||
| L-008A | PHOENIX PEPTIDE | 88 peptides | EUR 6067.44 |
C28 optimized peptide 6 (Human) |
|||
| 073-82 | PHOENIX PEPTIDE | 100 μg | EUR 235.44 |
Peptide YY (PYY) (Human) - EIA Kit |
|||
| EK-059-01 | PHOENIX PEPTIDE | 96 wells | EUR 617.76 |
Peptide YY (PYY) (Human) - RIA Kit |
|||
| RK-059-01 | PHOENIX PEPTIDE | 125 tubes | EUR 814.32 |
Cancer-Targeting Peptide Library |
|||
| L-015 | PHOENIX PEPTIDE | 289 peptides | EUR 7253.28 |
pro-Opionmelanocortin / J Peptide |
|||
| 022-22 | PHOENIX PEPTIDE | 200 μg | EUR 177.12 |
Galanin-Like Peptide (GALP) (Rat) |
|||
| 026-52 | PHOENIX PEPTIDE | 100 μg | EUR 282.96 |
PACAP-Related Peptide (PRP) (Rat) |
|||
| 052-11 | PHOENIX PEPTIDE | 200 μg | EUR 86.4 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - Purified IgG Antibody |
|||
| G-064-01 | PHOENIX PEPTIDE | 400 μg | EUR 438.48 |
Pri Peptide from sORF pri RNA |
|||
| 069-77 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
Kemptide / Phosphate Acceptor Peptide |
|||
| 058-16 | PHOENIX PEPTIDE | 500 μg | EUR 36.72 |
Bioactive Secretory Peptide Library |
|||
| L-009 | PHOENIX PEPTIDE | 1016 peptides | EUR 31350.24 |
u PAR (84-95) Scrambled Peptide |
|||
| 072-47 | PHOENIX PEPTIDE | 200 μg | EUR 177.12 |
Crustacean Cardioactive Peptide (CCAP) |
|||
| 047-24 | PHOENIX PEPTIDE | 500 μg | EUR 86.4 |
Virus Replication Inhibiting Peptide |
|||
| 070-85 | PHOENIX PEPTIDE | 5 mg | EUR 160.92 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - I-125 Labeled |
|||
| T-064-07 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
Annexin A1 Binding Peptide, IF7CRR |
|||
| 025-72 | PHOENIX PEPTIDE | 200 μg | EUR 184.68 |
Galanin-Like Peptide (GALP) (Human) |
|||
| 026-51 | PHOENIX PEPTIDE | 100 μg | EUR 230.04 |
Gastrin Releasing Peptide (GRP) (Rat) |
|||
| 027-32 | PHOENIX PEPTIDE | 100 μg | EUR 160.92 |
FMRF-Like Peptide (Helix aspersa) |
|||
| 047-31 | PHOENIX PEPTIDE | 1 mg | EUR 27 |
PACAP-Related Peptide (PRP) (Human) |
|||
| 052-10 | PHOENIX PEPTIDE | 200 μg | EUR 86.4 |
Scrambled Control for Pri Peptide |
|||
| 069-78 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
Alzheimer Fingerprint Peptide Library |
|||
| L-011 | PHOENIX PEPTIDE | 85 peptides | EUR 6529.68 |
Peptide YY (PYY) (1-36)-Gly (Human) |
|||
| 059-07 | PHOENIX PEPTIDE | 100 μg | EUR 295.92 |
Peptide YY (PYY) (3-36)-Gly (Human) |
|||
| 059-08 | PHOENIX PEPTIDE | 100 μg | EUR 282.96 |
Peptide YY (PYY) (2-36)-Gly (Human) |
|||
| 059-11 | PHOENIX PEPTIDE | 100 μg | EUR 267.84 |
Peptide YY (PYY) (4-36)-Gly (Human) |
|||
| 059-12 | PHOENIX PEPTIDE | 100 μg | EUR 267.84 |
Gastrin Releasing Peptide (GRP) (Frog) |
|||
| 027-33 | PHOENIX PEPTIDE | 100 μg | EUR 160.92 |
Small Cardioactive Peptide A (SCPA) |
|||
| 047-76 | PHOENIX PEPTIDE | 1 mg | EUR 64.8 |
Epidermal Growth Factor Receptor Peptide (985-996) |
|||
| 030-05 | PHOENIX PEPTIDE | 500 μg | EUR 102.6 |
T3 Peptide / Tumstatin (69-88) (Human) |
|||
| 016-50 | PHOENIX PEPTIDE | 100 μg | EUR 255.96 |
T7 Peptide / Tumstatin (74-98) (Human) |
|||
| 016-51 | PHOENIX PEPTIDE | 100 μg | EUR 255.96 |
Kinetensin / Neurotensin Related Peptide |
|||
| 048-01 | PHOENIX PEPTIDE | 500 μg | EUR 58.32 |
Galanin-Like Peptide (GALP) (Porcine) |
|||
| 026-50 | PHOENIX PEPTIDE | 100 μg | EUR 230.04 |
Gastrin Releasing Peptide (GRP) (Human) |
|||
| 027-07 | PHOENIX PEPTIDE | 200 μg | EUR 119.88 |
Gastrin Releasing Peptide (GRP) (Mouse) |
|||
| 027-40 | PHOENIX PEPTIDE | 100 μg | EUR 160.92 |
PGMtide Control Peptide - Cy3 Labeled |
|||
| FC3-040-70 | PHOENIX PEPTIDE | 1 nmol | EUR 925.56 |
PGMtide Control Peptide - FAM Labeled |
|||
| FG-040-70A | PHOENIX PEPTIDE | 5 nmol | EUR 537.84 |
Growth Blocking Peptide - FAM Labeled |
|||
| FG-046-92A | PHOENIX PEPTIDE | 1 nmol | EUR 336.96 |
Chop-Suey / Variety Peptide Library |
|||
| L-001 | PHOENIX PEPTIDE | 238 peptides | EUR 7400.16 |
Peptide F (Bovine) - I-125 Labeled |
|||
| T-024-58 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
Fractalkine Chemokine Domain peptide (41-52) (Human) |
|||
| 026-82 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
Fractalkine Chemokine Domain peptide (53-60) (Human) |
|||
| 026-83 | PHOENIX PEPTIDE | 200 μg | EUR 135 |
Fractalkine Chemokine Domain peptide (60-71) (Human) |
|||
| 026-84 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
F3 Peptide (4-13) / HMGN2 Fragment 3 (4-13) |
|||
| 004-13 | PHOENIX PEPTIDE | 200 μg | EUR 177.12 |
FMRF-Like Peptide ( Lymnae stagnalis) |
|||
| 047-30 | PHOENIX PEPTIDE | 5 mg | EUR 129.6 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - Purified IgG Antibody |
|||
| G-064-07 | PHOENIX PEPTIDE | 400 μg | EUR 438.48 |
Hypocholesterolemic Peptide / IIAEK (Bovine) |
|||
| 028-37 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
[D-Ala1]-Peptide T - Biotin Labeled |
|||
| B-057-02 | PHOENIX PEPTIDE | 100 μg | EUR 316.44 |
Gastrin Releasing Peptide (GRP) (Porcine) |
|||
| 027-13 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
Delta-Sleep-Inducing Peptide (DSIP) |
|||
| 070-22 | PHOENIX PEPTIDE | 500 μg | EUR 27 |
[Thr5]-Speract / Sperm Activating Peptide |
|||
| 070-71 | PHOENIX PEPTIDE | 1 mg | EUR 114.48 |
Kappa-Receptor, C-terminal peptide |
|||
| 002-98 | PHOENIX PEPTIDE | 100 μg | EUR 469.8 |
Angiotensin II - constrained peptide 1 |
|||
| 004-09 | PHOENIX PEPTIDE | 500 μg | EUR 165.24 |
VEGFR binding peptide KH / QKRKRKKSRKKH |
|||
| 007-58 | PHOENIX PEPTIDE | 100 μg | EUR 158.76 |
Now it is clear that IAPP can also have a pathological role in AD, reducing cognitive function. IAPP harms blood-brain barriers, directly interacting and co-deposits with Aβ, promoting dementia associated with diabetes. IAPP can cause metabolic dysfunction in the brain, which leads to other diabetes advertisements. Thus, here we discuss the IAPP associations with diabetes, Aβ and dementia, in the context of what we specify “brain diabetes phenotype”. The hypothesis such approach helps establish a conceptual framework for IAPP-based drugs in the future against AD.
